Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P; KEYNOTE-355 Investigators. Cortes J, et al. Among authors: masuda n. N Engl J Med. 2022 Jul 21;387(3):217-226. doi: 10.1056/NEJMoa2202809. N Engl J Med. 2022. PMID: 35857659 Clinical Trial.
Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival.
Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, Kusama M, Yamazaki K, Hisamatsu K, Sato Y, Kashiwaba M, Kaise H, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Takatsuka Y; Japan Breast Cancer Research Group (JBCRG). Toi M, et al. Among authors: masuda n. Breast Cancer Res Treat. 2008 Aug;110(3):531-9. doi: 10.1007/s10549-007-9744-z. Epub 2007 Sep 19. Breast Cancer Res Treat. 2008. PMID: 17879158 Clinical Trial.
Low nuclear grade but not cell proliferation predictive of pathological complete response to docetaxel in human breast cancers.
Miyoshi Y, Kurosumi M, Kurebayashi J, Matsuura N, Takahashi M, Tokunaga E, Egawa C, Masuda N, Kim SJ, Okishiro M, Yanagisawa T, Ueda S, Taguchi T, Tamaki Y, Noguchi S; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Miyoshi Y, et al. Among authors: masuda n. J Cancer Res Clin Oncol. 2008 May;134(5):561-7. doi: 10.1007/s00432-007-0319-5. Epub 2007 Oct 16. J Cancer Res Clin Oncol. 2008. PMID: 17938960
Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers.
Miyoshi Y, Kurosumi M, Kurebayashi J, Matsuura N, Takahashi M, Tokunaga E, Egawa C, Masuda N, Kim SJ, Okishiro M, Yanagisawa T, Ueda S, Taguchi T, Tamaki Y, Noguchi S; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Miyoshi Y, et al. Among authors: masuda n. Cancer Lett. 2008 Jun 8;264(1):44-53. doi: 10.1016/j.canlet.2008.01.015. Epub 2008 Feb 15. Cancer Lett. 2008. PMID: 18280644
Molecular detection of lymph node metastases in breast cancer patients: results of a multicenter trial using the one-step nucleic acid amplification assay.
Tamaki Y, Akiyama F, Iwase T, Kaneko T, Tsuda H, Sato K, Ueda S, Mano M, Masuda N, Takeda M, Tsujimoto M, Yoshidome K, Inaji H, Nakajima H, Komoike Y, Kataoka TR, Nakamura S, Suzuki K, Tsugawa K, Wakasa K, Okino T, Kato Y, Noguchi S, Matsuura N. Tamaki Y, et al. Among authors: masuda n. Clin Cancer Res. 2009 Apr 15;15(8):2879-84. doi: 10.1158/1078-0432.CCR-08-1881. Epub 2009 Apr 7. Clin Cancer Res. 2009. PMID: 19351770
Predictive factors for anthracycline-based chemotherapy for human breast cancer.
Miyoshi Y, Kurosumi M, Kurebayashi J, Matsuura N, Takahashi M, Tokunaga E, Egawa C, Masuda N, Kono S, Morimoto K, Kim SJ, Okishiro M, Yanagisawa T, Ueda S, Taguchi T, Tamaki Y, Noguchi S. Miyoshi Y, et al. Among authors: masuda n. Breast Cancer. 2010 Apr;17(2):103-9. doi: 10.1007/s12282-009-0152-6. Epub 2009 Aug 6. Breast Cancer. 2010. PMID: 19657712 Review.
1,174 results